|
|
Issue 1, July 2004
Transgenic Plants: A Budding Controversy Stems from Consumer
Concerns
Larissa Parsley, Science Journalist
Biology and English, William Carey College
parsley@jyi.org
 |
Figure
1. Plant cloning through tissue culture propagation. One
of genetic engineering’s most powerful tools, cloning
results in a “replica” of the original organism.
In this diagram, a plant is shown being cloned by isolating
its root cells and allowing them to grow in a nutrient-rich
culture. The root cells will de-differentiate into calluses,
or masses of non-specialized cells. These calluses can then
be exposed to various plant hormones, stimulating them to
grow and eventually develop into plants similar to the original
plant. (Source: www.science.howstuffworks.com) |
What
once was a quick stop at the local grocery store now has become
a series of carefully planned purchases for many consumers. All
around, signs proclaim “organic” and “all natural”
– descriptions that, in the past, applied to all foods found
in the grocery store. What products warrant so much attention and
demand so much purchasing consideration? Fresh fruits and vegetables,
which used to be chosen based solely on cost and appearance, are
now subjected to a new criterion: have the plants been genetically
modified in any way? If so, how does this affect consumers and their
purchasing choices? What advantages and risks come with genetically
modified plants? Do government agencies have a responsibility to
regulate the production and labeling of genetically modified plants?
Answers to these questions are inherently complex and can only become
clear once an understanding of genetic modification is reached and
the major issues of genetically modifying plants are addressed in
an objective manner.
Genetic engineering 101:
When
words like “genetic engineering” enter the conversation,
some minds tend to jump to conclusions, conjuring up images of an
army of cloned Hitlers, a dog with two heads, or purple corn on-the-cob.
However, a genetically engineered organism (often referred to as “genetically
modified”) more than likely has undergone very little change
in terms of its genetics. In the realm of food and medical biotechnology,
a plant or animal is affected by genetic engineering in three possible
ways:
- Certain genes of the plant or animal are altered.
These genes may be “turned on” or “turned off”
to control the expression of certain traits in the organism.
- A clone of the plant or animal is produced.
Using cells from the host plant or animal, a clone is allowed
to develop which is genetically identical to the host.
- New genetic material (DNA) is introduced into the genome
of the plant or animal. Genes from an organism of a completely
different species may be inserted into the plant or animal’s
genome to confer new characteristics on the plant or animal. This
method of genetic engineering is known as transgenic modification,
and the organism is now said to contain recombinant (a new combination
of) DNA. When plants are genetically modified for food or medical
purposes, the third method of modification is most common.
Although
transgenics is a relatively new modification technique, the manipulation
of plants to achieve certain traits or crop yields is not so new.
Since prehistoric times, farmers and gatherers have used selective
breeding to create hybrids of plants or to produce healthier versions
of a weaker plant. In more recent years, as our understanding of
genetic expression control deepens, our methods for manipulating
an organism’s characteristics become increasingly more technical
and specific.
The world was introduced to its first commercialized, genetically
modified plant in 1992, when the biotech firm Calgene marketed its
FlavrSavr© tomato. Because of its genetic modifications, this
“new and improved” tomato resisted ripening and remained
firm much longer than its unmodified counterpart. That same year,
the U.S. Food and Drug Administration (FDA) announced that genetically
engineered foods are “not inherently dangerous” and
therefore require no special regulation.
 |
Figure
2. Antibiotic-resistance marker genes. A gene that will
confer antibiotic resistance to the plant is included in the
same vector containing the gene which will give the plant
its new, desired characteristic. If the plant exhibits antibiotic
resistance, it can be deduced that the plant will also exhibit
the new characteristic. (Source: BBC News) |
The
FDA’s assurances surrounding the safety of genetically modified
foods may have placated consumer concerns 11 years ago, but new
health risks, economic effects, and ethical concerns are on the
rise in the minds of many consumers. The question not only remains
but inherently demands to be answered: What are the benefits and
dangers of genetically modifying plants, and do these benefits ultimately
outweigh the risks involved in such a manipulation of nature?
Advantages of genetically modified plants
Most
genetically modified plants (GMPs) are crops that are modified to
improve food quality or production, such as Calgene’s tomato.
Enhancing taste, appearance, and shelf life of certain crops has
obvious economic benefits for the consumer, and although consumer
satisfaction is a very positive aspect of GMPs, there exist many
additional, wide-reaching advantages as well.
Some genetic modifications are designed to improve the quality and
quantity of crop yield of a particular plant. For example, a corn
plant may be engineered in such a way so as to generate a certain
protein that increases the efficiency of its growth cycle, therefore
producing more corn in a shorter amount of time than the traditional
corn plant.
Another method of increasing crop yield is to confer resistance
in plants normally damaged or destroyed by insects. A genetic modification
may result in a new color pigment in the plant’s leaves that
wards off previously persistent insects, so that the plant is allowed
to develop normally into a healthy source of food. A similar method
of protecting crops involves genetically instilling herbicide tolerance
and pesticide resistance in plants that farmers want to remain unaffected
by such chemicals. If a weed-killing herbicide also harmed a farmer’s
wheat crop, genetic modification could confer herbicide resistance
in the wheat so that it would be unaffected by the herbicide meant
to destroy the weeds.
An increased crop yield, attained through any method, could lower
costs for consumers, because a particular crop is “mass produced”
with less time and labor than was previously necessary. But while
economic benefits appear to be the driving force behind these genetic
modifications, GMPs offer other promising possibilities in the area
of medical biotechnology.
 |
Figure
3. Recent public opinion concerning mandatory labeling
of genetically modified foods. From 1998 to 2001, there was
an 11% increase in public support for mandatory labeling.
This steady increase demonstrates a growing public concern
and consumer desire to know what types of food are being purchased
and eaten. (Source: Americans & The World: Public
Opinions on International Affairs) |
Developing
vaccines and antibiotics has long been one of the most pressing
responsibilities and most noble goals of medical researchers. With
the help of genetic engineering, reaching that goal is becoming
more realistic. In recent years, biotechnologists have developed
“edible vaccines,” foods that contain the power to protect
against disease and must only be eaten to be effective. These edible
vaccines would certainly provide a more practical method of disease
control than traditional immunizations and could come at much less
cost and inconvenience for the consumer. Tests are already underway
to determine the effectiveness of edible vaccines against the Hepatitis
B virus and for the bacterial disease cholera.
Plants also may be modified to work as “antibiotic factories,”
mass-producing bacterial antibiotics at a much faster rate than
scientists can in a laboratory. An increased supply of antibiotics
may alleviate some of the financial struggles that consumers face
against high-priced medications, and these genetic modifications
may also lead to the development of new and more effective antibiotics.
With our increasing knowledge of plant genetics and the techniques
necessary to perform genetic modification, the possibilities seem
endless. Plants can be cloned for study, be made to resist pesticides,
and be modified to protect a child from contracting cholera. The
economic and medical benefits are no less than amazing, but what
is the price of this supposed “gift” of genetic modification?
Concerns
surrounding genetically modified plants
 |
Figure
4. Policy cartoon by Reymond Page. This image, one of
many of its kind, depicts the growing public distrust and
suspicion of biotech companies and their policies. In this
cartoon, the artist addresses the possibility of genetic modifications
modifying more than the scientist’s intended target
and the seemingly casual manner in which organisms are modified.
(Source: Action Group on Erosion, Technology, and
Concentration) |
Ironically,
many of the economic and medical advantages associated with the
genetic modification of plants are considered to be the biological
disadvantages of the same process. While many consumers
are hesitant to embrace GMPs for personal, philosophical, or religious
reasons, legitimate health and ecological risks do arise when a
plant (or any other organism) is genetically modified.
When a plant receives an infusion of foreign DNA that introduces
a new trait, the plant also receives a “marker gene,”
an extra gene biochemically linked to the foreign DNA. This marker
gene is incorporated into the plant’s genome along with the
foreign DNA and codes for another trait often more quickly and easily
recognizable than the trait from the foreign DNA. In this way, scientists
can confirm that the plant successfully received and incorporated
the new DNA without waiting until the plant completes a growing
season. Often, this marker gene codes for a type of antibiotic resistance
in the plant, a trait easily tested soon after genetic modification
occurs. If the plant shows resistance, then the modification was
successful, and the plant should exhibit the desired trait.
This quick test comes with an inherent risk, however; many health
officials are concerned that the plant’s antibiotic resistance
gene might be transferred to bacterial cells in the human body after
the plant is ingested. If this transfer occurs, bacteria in the
body could become resistant to the selected antibiotic and therefore
become a potential public health concern.
The transfer of pollen between modified and non-modified plants
could also create health and ecological problems involves. It is
possible for recombinant DNA to be incorporated into an unintended
host during pollination. Controlling the spread of engineered genetic
material to plants that were never meant to be modified poses a
deeper question: Can we realistically and effectively control genetic
modification so that biodiversity is maintained?
Many consumers also have concerns regarding the transfer of allergens
in GMPs. The severe allergic reactions associated with peanuts and
other nuts could become a health risk with new, genetically modified
plant varieties. A strawberry plant that previously provoked no
allergic reaction in an individual could, after genetic modification,
result in a new and never-before-seen immune response.
Taking a step back from the health and biology of the situation,
economics accounts for a significant disadvantage in the minds of
the GMP-wary. While supporters of GMPs claim that the increased
crop yield can help provide food for developing countries, many
organizations feel that these countries will never see this surplus
of food because it is not in the economic interest of the companies
that produce it. Anuradha Mittal, a co-director for Food First,
a non-profit food policy group based in Oakland, California, questions
how a biotech takeover of food production could possibly benefit
the farming community and developing countries: “How can corporations
expect farmers to believe this technology is in their best interests?
It's about maximizing corporate profits, not ending world hunger."
Indeed,
valid health, ecological, and economic risks exist with regards
to genetic modification. However, there is always more to the story.
If the controversy surrounding the use of GMPs centered only on
safety and economics, the decision to support or reject GMPs would
simply be a matter of weighing personal benefits against personal
risks, for example asking whether the transfer of antibiotic resistance
an acceptable risk if that same technology could provide a vaccine
against HIV. However, most consumers have more than safety and economics
on their minds when they consider genetic modification, and these
additional considerations cannot be so easily addressed.
A deeper controversy: Social and ethical concerns
 |
Figure
5. Wheat blows in the wind. The visual similarities between
modified and non-modified crops make it impossible for the
consumer to detect any modifications without seeing a label
that describes the food as modified. Consumer trust is simply
one of many facets to the controversy surrounding genetically
modified food and the labels that might accompany such food. |
Before
a genetically modified product can be released onto the public market,
it must pass a test of “substantial equivalence,” a
term that refers to the relative safety of the new product as compared
to its traditional counterpart. If the new product is found to be
as safe as or safer than the traditional product, then it is declared
to be “substantially equivalent” and can be commercialized
without any special regulation. For the consumer whose main concerns
about GMPs lie in safety and health, this equivalence test may provide
some comfort.
However, most consumers have doubts about GMPs on a less easily
defined level. In addition to the substantial equivalence test,
companies and regulatory agencies consider three main criteria when
evaluating a new genetically modified product: efficacy, quality,
and safety. It has been often noted that a fourth criterion unofficially
exists: morality. Ironically, this criterion, more so than the other
three combined, often dictates what action the company or agency
will take with regards to marketing the product.
Many consumers are hesitant to support a science that they believe
is “playing God” with nature. Other consumers, either
for religious or personal reasons, may want to avoid eating plants
which contain bacterial, animal, or human genes and believe that
such plants should not be allowed to enter the human food chain.
Although many consumers do make informed decisions concerning GMPs
from a health, economic, or even an ethical standpoint, at times
a lack of familiarity with the process of genetic modifications
and its affects leads to a suspicion which makes an objective decision
difficult. Consumers’ doubts about GMPs may simply arise from
a fear of the unknown and a distrust of the scientific community
which does not always clearly communicate its objectives and methods
to society.
So, what will it take to alleviate health and safety worries in
the minds of the consumers? One possible solution, which is, ironically,
a new controversy in itself, is being explored.
Labeling: Will it solve the problem?
At
the local grocery store we are faced with a purchasing dilemma:
as the “organic” and “all natural” signs
are displayed around us, we wonder, “Are all of the products
without these signs genetically modified?” If so, how have
they been modified? If you were a consumer in this grocery store,
would you want to know that the fruits and vegetables you are buying
have undergone genetic modification?
Most consumers would answer “yes” to this question,
which sparks yet another controversy that is not easily resolved
with equivalence tests and FDA research reports. Biotech companies
have displayed a long-standing opposition to the mandatory labeling
of their genetically modified products, citing time, manpower, and
finances as limiting factors. Consumers, on the other hand, often
feel that this unwillingness to label demonstrates secrecy and unethical
motives on the part of the company, which only magnifies the distrust
and suspicion already harbored by many consumers.
Companies argue that labeling for health and safety purposes would
not greatly affect the consumer’s purchasing choice because
products such as cigarettes and alcohol are clearly labeled with
health warnings yet are purchased constantly, seemingly without
reservation. However, the fourth criterion of morality once again
enters the picture: many consumers feel they have a right to know
what products have been genetically modified so they might avoid
them for religious or ethical reasons. For example, a vegetarian
may choose to abstain from eating a fruit which contains animal
genes, or a religious group may want to avoid genetically modified
products that contain genes from an animal they consider to be sacred.
In addition to moral and ethical concerns, the simple matter of
safety is reason enough for many consumers to demand labeling. Even
if a particular food has been deemed “safe and healthy”
for public consumption by a government research trial, the consumer
may still have reservations with regard to his or her personal health.
Robert Thiel, Ph.D., N.D., president of the Neuropathic Medical
Association at California State University, warns that government
agencies may be reluctant to enforce labeling because they believe
a GMP is not fundamentally different than its unmodified counterpart.
“The FDA currently requires no labeling because it believes
that genetically modified foods are not significantly different
than hybrids developed by cross breeding. Genetically modified foods
are different, however, from hybrids.” This differentiation,
which appears to stem from academic hair-splitting, is truly fundamental
in the labeling controversy. As Thiel states, “There is phenomenal
potential for harm.”
The clear and appropriate labeling of such products must become
a reality before the consumer market as a whole can begin to accept
the role of genetically modified organisms as a source of food,
medicine, and other everyday products. When labeling becomes as
common as genetic modification itself, consumers will then be free
to exercise their choice about this issue, not only with words,
but with purchasing action. “The mere fact that labels are
there changes consumers' perception of risk from one that is involuntary
to one that is voluntary,” concludes Lydia Zepeda, an associate
professor of consumer science at the University of Wisconsin-Madison.
“Once you have a label that's assured by a government agency,
there's a lot of trust in that. Some agreed-upon standard will end
up enhancing consumer confidence.”
Transgenic
plants: Have they truly taken root?
It’s
clear transgenic plants are here to stay; however, must the controversy
stay along with them? Don Glickman and Vin Weber, advisors to the
Pew Initiative on Food and Biotechnology, answer with an emphatic
“no.” “Rather than fight about whether the biotech
genie is good or bad,” they say, “all parties need to
sit down and collectively figure out how to manage it.” The
controversy appears to be as detrimental to the public as any risk
associated with the genetically modified plants themselves. Glickman
and Weber pose a warning aimed at the destructive international
effects of a continued controversy. “Without efforts to find
agreement, we risk wrecking the current round of trade negotiations,
increasing the schism between the European Union and the United
States, and impeding the use of a technology that has such great
promise for the future.” This schism refers to the strained
relations between the EU and the United States with regard to the
regulation of genetically modified organisms. The EU maintains stricter
standards for labeling GMPs and also for the tracking of foods that
may contain modified ingredients. Because of these regulatory differences,
conflict often arises when GMPs are transferred between the EU and
the United States.
The advantages and risks associated with genetically modified plants
are easily explored, yet closure or compromise on the issue seems
infinitely far away. What must be examined more closely are the
underlying issues that compound the controversy, such as ethical
concerns and labeling. These issues are not likely to disappear;
however, neither is the science of genetic modification. Companies
will emphasize the benefits of GMPs while consumers will question
the health and ethical risks involved. Companies will downplay the
importance of labeling while consumers will demand to know the genetic
nature of the products they buy. However, transgenic modification
has indeed become a way of life in the biotechnology world, and
the techniques involved are becoming more specific and effective
every day.
What
is the bottom line? Genetically modified plants are here to stay,
but perhaps the next time you look around your local grocery store,
you might look at that ear of corn a little more closely and consider
the issues surrounding such a seemingly innocent source of nourishment.
Further Reading
“History of Genetically Modified Organisms (GMOs).” American
Radio Works. <http://www.americanradioworks.org/features/gmos_india/history.html>
“Transgenic Crops: An Introduction and Resource Guide.”
Colorado State University.
<http://www.colostate.edu/programs/lifesciences/TransgenicCrops/evaluation.html>
“Bioengineered Foods: Will They Cause Allergic Reactions?”
U.S. Food and Drug Administration. <http://www.cfsan.fda.gov/~dms/pubalrgy.html>
“Report on Consumer Focus Groups on Biotechnology. U.S. Food
and Drug Administration. <http://www.cfsan.fda.gov/~comm/biorpt.html>
Smith, John E. “Public Perception of Biotechnology.” Basic
Biotechnology. Eds. Colin Ratledge and Bjorn Kristiansen. Cambridge,
UK: Cambridge University Press, 2002. 3-16.
Gaskell, George, et al. “Worlds Apart? The Reception of Genetically
Modified Foods in Europe and the U.S.” Science (25):
384-387. 16 July 1999.
Peter Pringle. Food, Inc: Mendel to Monsanto – The Promises
and Perils of the Biotech Harvest. New York: Simon & Schuster.
2003.
Journal
of Young Investigators. 2004. Volume Eleven.
Copyright © 2004 by Larissa Parsley and JYI. All rights reserved. |
|